Přihlásit se Zaregistrujte se zdarma

Dluh/Vlastní kapitál společnosti Midatech Pharma Plc

Jaká je hodnota metriky Dluh/Vlastní kapitál společnosti Midatech Pharma Plc?

Hodnota metriky Dluh/Vlastní kapitál společnosti Midatech Pharma Plc je 0.75

Jaká je definice metriky Dluh/Vlastní kapitál?



Poměr dluhu k vlastnímu kapitálu (debt to equity ratio) udává podíl vlastního kapitálu a cizích zdrojů na financování majetku společnosti.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Dluh/Vlastní kapitál společností v sektoru Health Care sektor na LSE ve srovnání se společností Midatech Pharma Plc

Čemu se věnuje společnost Midatech Pharma Plc?

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Firmy s metrikou dluh/vlastní kapitál podobnou společnosti Midatech Pharma Plc